Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Nov;16(6):761-771.
doi: 10.1007/s11523-021-00849-8. Epub 2021 Oct 23.

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study

Eliza A Hawkes  1 , Tycel Phillips  2 , Lihua Elizabeth Budde  3 , Armando Santoro  4   5 , Nakhle S Saba  6 , Fernando Roncolato  7 , Gareth P Gregory  8 , Gregor Verhoef  9 , Fritz Offner  10 , Cristina Quero  11 , John Radford  12 , Krzysztof Giannopoulos  13 , Don Stevens  14 , Aron Thall  15 , Bo Huang  16 , A Douglas Laird  15 , Robin Sandner  17 , Stephen M Ansell  18
Affiliations
Clinical Trial

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study

Eliza A Hawkes et al. Target Oncol. 2021 Nov.

Abstract

Background: Relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is associated with a poor prognosis despite the availability of multiple treatment options. Preliminary evidence suggests that DLBCL may be responsive to programmed death ligand 1 (PD-L1)/programmed death 1 inhibitors.

Objective: The JAVELIN DLBCL study was conducted to assess whether a combination of agents could augment and sustain the antitumor immunity of avelumab, an anti-PD-L1 antibody, in R/R DLBCL.

Methods: This was a multicenter, randomized, open-label, parallel-arm study with a phase Ib and a phase III component. Reported here are the results from the phase Ib study, wherein 29 adult patients with DLBCL were randomized 1:1:1 to receive avelumab in combination with utomilumab (an immunoglobulin G2 4-1BB agonist) and rituximab (arm A), avelumab in combination with utomilumab and azacitidine (arm B), or avelumab in combination with bendamustine and rituximab (arm C). The primary endpoints were dose-limiting toxicities and objective response as assessed by the investigator per Lugano Response Classification criteria.

Results: Of the seven patients in arm A, one (14.3%) experienced two grade 3 dose-limiting toxicities (herpes zoster and ophthalmic herpes zoster); no dose-limiting toxicities were reported in arms B or C. No new safety concerns emerged for avelumab. One partial response was reported in arm A, three complete responses in arm C, and no responses in arm B. Given the insufficient antitumor activity in arms A and B and the infeasibility of expanding arm C, the study was discontinued before initiation of the phase III component.

Conclusions: The low level of clinical activity suggests that PD-L1 inhibitor activity may be limited in R/R DLBCL. CLINICALTRIALS.

Gov identifier: NCT02951156.

PubMed Disclaimer

Conflict of interest statement

EAH has received honoraria for advisory work for Roche, Bristol Myers Squibb, Celgene, MSD, Gilead, Antigene, Janssen, and AstraZeneca; travel expenses and honoraria for speaker work for Roche; and research funding from Roche, Merck, Bristol Myers Squibb, Celgene, MSD, Gilead, Antigene, Janssen, and AstraZeneca. TP has acted in consultancy/advisory roles for AbbVie, ADC Therapeutics, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Celgene, Incyte, Genentech, Gilead, Kite, and Pharmacyclics and has received research funding from AbbVie, Bayer, BMS/Celgene, Genentech, and Incyte. AS has acted in consultancy/advisory roles for Bristol Myers Squibb, Servier, Gilead, Pfizer, Eisai, Bayer, MSD, Arqule, and Sanofi and has undertaken speaker bureau work for Takeda, Bristol Myers Squibb, Roche, AbbVie, Amgen, Celgene, Servier, Gilead, AstraZeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, Bayer, and MSD. NSS has acted in consultancy/advisory roles for Kite, AbbVie, Janssen, and Kyowa Kirin and has undertaken speaker bureau work for Janssen and AbbVie. GPG has acted in advisory roles for Roche, Novartis, Gilead, and Janssen; and has received honoraria from Roche, AbbVie, and Novartis and research funding from MSD, BeiGene, and Janssen. JR has acted in consultancy/advisory roles for Takeda, Bristol Myers Squibb, ADC Therapeutics, and Novartis; owns stock in AstraZeneca and ADC Therapeutics; has received honoraria from Takeda, ADC Therapeutics, and Bristol Myers Squibb; has provided speaker/expert testimony for Takeda and ADC Therapeutics; and has received research funding from Takeda. KG has received honoraria from and served as a consultant for Amgen, AbbVie, BMS/Celgene, Janssen, Sanofi-Genzyme, Takeda, Novartis, Pfizer, Sandoz, and BeiGene and has received research funding from Amgen, AbbVie, BMS/Celgene, Janssen, Sanofi-Genzyme, Takeda, and Novartis. AT, BH, ADL, and RS are employees of and report stock ownership in Pfizer. SMA has received research funding (paid to his institution) for clinical trials from Bristol Myers Squibb, Seattle Genetics, Takeda, AI Therapeutics, Affimed, Pfizer, Trillium, Regeneron, and ADC Therapeutics. LEB, FR, GV, FO, CQ, and DS have no conflicts of interest that are directly relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Time to and duration of response. Time to tumor response and duration of response are shown for one patient in the avelumab/utomilumab/rituximab arm (partial response) and three patients in the avelumab/bendamustine/rituximab arm (all complete responses). Based on investigator assessment (Cheson et al. [37] criteria)
Fig. 2
Fig. 2
PFS per investigator assessment based on Cheson et al. [37] criteria. CI confidence interval, NE not evaluable, PFS progression-free survival
Fig. 3
Fig. 3
Overall survival. CI confidence interval, NE not evaluable, OS overall survival
See this image and copyright information in PMC

References

    1. Vacirca JL, Acs PI, Tabbara IA, et al. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol. 2014;93:403–409. doi: 10.1007/s00277-013-1879-x. - DOI - PMC - PubMed
    1. Narang RS, Manchanda AS, Kaur H. Evaluation of a case of diffuse large B-cell lymphoma. J Oral Maxillofac Pathol. 2019;23:7–11. doi: 10.4103/jomfp.JOMFP_100_17. - DOI - PMC - PubMed
    1. Sehn LH. Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program. 2012;2012:402–409. doi: 10.1182/asheducation-2012.1.402. - DOI - PubMed
    1. NCCN Clinical Practice Guidelines in Oncology. B-cell Lymphomas. v4.2021. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed 17 June 2021.
    1. Maddocks K. Novel targets in aggressive lymphoma. Hematology Am Soc Hematol Educ Program. 2020;2020:101–106. doi: 10.1182/hematology.2020000093. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data